SOURCES SOUGHT
A -- Drug Testing Facility
- Notice Date
- 8/1/2008
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- SS-NIH-NICHD-09-05
- Archive Date
- 9/3/2008
- Point of Contact
- Ross Kelley,, Phone: 301-435-6960
- E-Mail Address
-
rk17a@nih.gov
- Small Business Set-Aside
- N/A
- Description
- This announcement is not a Request for Proposals (RFP) and does not commit the Government to award a contract now or in the future. No solicitation is available at this time. The purpose of this synopsis is to identify small business organizations with requisite qualifications to provide the services stated herein. Based on capability statements received in response to this Sources Sought Announcement an acquisition may be solicited as a 100% small business set-aside. All small business organizations (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) are encouraged to respond to this notice. This requirement is assigned a code of 541710 in the North American Industry Classification System (NAICS), and the size standard of 500 employees or less. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/NIH, seeks capability statements from interested and qualified potential sources to assay hundreds of submissions annually for classical endocrine and anti-fertility activity and to establish potency ratios (in terms of standards) for those that exhibit significant effects. The organization should also have the capability to develop methods for determining the duration of biological activity following oral, subcutaneous and topical (transdermal, transvaginal, etc) administration and to evaluate the potential clinical utility of new compositions of matter and formulation. Organizations must also be capable of performing a wide range of screens, assays, safety tests and analytical procedures for the evaluation of new compounds, formulations and delivery systems. The results of theses tests may be used to support patent applications NICHD. Organizations that submit capability statements in response to this notice will be evaluated against the following technical areas of experience and expertise: 1. The organization must have the capability to conduct work in an AAALAC-accredited animal facility. 2. The capability to conduct Toxicology studies, including acute, subacute, subchronic, chronic, reproductive and genetic. 3. The capability to conduct Rabbit vaginal irritation testing for the evaluation of formulations of spermicides and microbicides to include both gross and histopathological examination of external genitalia and cervix. Services of a board certified pathologist are required for performance of both gross and microscopic examinations. This test is usually performed under "Good Laboratory Practices" (GLP) Guidelines so that, if necessary, the results may be submitted to the FDA in support of a Notice of Claimed Investigational Exemption for a New Drug (IND) initiation of clinical investigations. New compounds and/ or formulations must have an IND before clinical work can proceed. 4. The capability to conduct contraceptive efficacy tests required to predict clinical activity of potential contraceptives. Dose-response and time related efficacy curves must be provided for comparison with various standards. 5. The capability to grow and maintain cell cultures for the conduct of in vitro assays required for evaluation of compounds. Theses assays include, but are not limited to, transfection of specific cell lines with estrogen and progesterone receptor expression plasmids and appropriate reporter constructs. These in vitro tests will permit a more thorough exploration of tissue-specific effects of a number of steroids, their antagonists, and other compounds exhibiting antifertility activities. Interested organizations that believe they possess the capabilities necessary to undertake this project should submit electronic copies in addition to two (2) hard copies of their capability statement, addressing the areas above. Please limit responses to fifteen (15) pages or less. Any proprietary information should be so marked. Written capability statements should be received by the Contracting Officer by no later than 4:00PM local time on August 19, 2008. Capability statements must identify the business status of the organization (i.e. educational institution, non-profit, large business, small business, 8 (a), or other corporate or non-corporate entity). NO COLLECT CALLS WILL BE ACCEPTED. RESPONDENTS MAY SUBMIT THEIR CAPABILITY STATEMENTS VIA E-MAIL IN ADDITION TO THE 2 HARD COPIES. See NUMBER NOTE 25. Responses should be no more than 15 pages. These pages exclude resumes. INQUIRIES Ross Kelley Contracting Officer The Eunice Kennedy Shriver National Institute of Child Health and Human Development 6100 Executive Boulevard, Suite 7A07, MSC 7510 Bethesda MD 20892-7510 Rockville, MD 20852 (for express/courier service) Telephone: 301-435-6960 Fax: 301-402-3676 E-mail: rk17a@nih.gov
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=1b282ce860c20f9fad424ae18bf78cf3&tab=core&_cview=1)
- Record
- SN01629191-W 20080803/080801222445-1b282ce860c20f9fad424ae18bf78cf3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |